Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke.

Name: Αlpha¹ Rigor Record — Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke.
Item: Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke.
Rating: 96
Author: Αlpha¹

Adeoye O, Broderick J, Derdeyn CP, Grotta JC, Barsan W, Bentho O, Berry S, Concha M, Davis I, Demel S, Elm J, Gentile N, Graves T, Hoffman M, Huang J, Ingles J, Janis S, Jasne AS, Khatri P, Levine SR, Majjhoo A, Panagos P, Pancioli A, Pizzella S, Ranasinghe T, Sabagha N, Sivakumar S, Streib C, Vagal A, Wilson A, Wintermark M, Yoo AJ, Barreto AD

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4.25★ (Strong), 0 critical, 2 high issues for “Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4.25 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) covered 2 of 6 reported means. The other 4 do not state their group size where the value is printed, and these checks need the count the mean was averaged over, so they were not checked.

Problems surfaced2 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 3 randomized trial with rigorous design, clear ethical approvals, and appropriate statistical methods. The main weaknesses are minor reporting gaps: the data sharing statement is not detailed, statistical software is not named, and a few copyedit issues exist.

Both reviewers independently scored all eight dimensions and agreed on all statuses. The study type is interventional. Non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification checked only 1 test; other statistics were not machine-verified.

3 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior trials with conflicting findings for argatroban and equivocal phase 2 results for eptifibatide, and explains the biological rationale for each drug. The premise logically leads to the trial objective of comparing these agents against placebo. Limitations of prior research are implicitly addressed by the design of a larger, phase 3 trial, though not explicitly framed as addressing prior limitations.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior trials and explaining the rationale for testing argatroban and eptifibatide as adjuncts to thrombolysis.

Evidence

direct quote[Introduction, paragraph 2]

“Two recent trials yielded conflicting findings regarding the benefit of argatroban in ischemic stroke.”